• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

The 'surprise' question may improve the accuracy of GPs in identifying death in patients with advanced stage IV solid-cell cancer
Commentary on: Moroni M, Zocchi D, Bolognesi D, et al.; on behalf of the SUQ-P group. The ‘surprise’ question in advanced cancer patients: a prospective study among general practitioners. Palliat Med 2014;28:,959–64. Context The ‘surprise’ question has been developed in order to improve the ability of clinicians to identify patients who are at risk of dying in the near future. The question, ‘Would I be surprised if this patient died in the next year?’ shifts the focus away from precise identification of dying patients to identifying patients who might be dying.1 This may enable mor...
Source: Evidence-Based Medicine - March 17, 2015 Category: Internal Medicine Authors: Rhee, J., Clayton, J. M. Tags: EBM Prognosis, Pancreas and biliary tract, Palliative care, Epidemiologic studies, General practice / family medicine, Stroke, Prostate Source Type: research

Patterns of thromboembolism in patients with advanced pancreatic cancer undergoing 1st-line chemotherapy with FOLFIRINOX or Gemcitabine/nab-paclitaxel
CONCLUSION: Patients with aPC undergoing palliative 1st-line chemotherapy with FOLFIRINOX or GN face a high risk for VTE/ATE and its diagnosis is linked to worse clinical outcomes. VTE-risk prediction models have limited ability to sub-stratify thrombotic events in this high-risk scenario.PMID:34255340 | DOI:10.1055/a-1548-4847
Source: Thrombosis and Haemostasis - July 13, 2021 Category: Hematology Authors: Jakob M Riedl Esther Schwarzenbacher Florian Moik Lena Horvath Antonia Gantschnigg Felix Renneberg Florian Posch Dominik A Barth Michael Stotz Martin Pichler Stefan Hatzl Simon Fandler-H öfler Paul Gressenberger Thomas Gary Philipp Jost Richard Greil Cih Source Type: research

SNHG11 ：A New Budding Star in Tumors and Inflammatory Diseases
CONCLUSION: LncRNA SNHG11 can serve as an early diagnostic biomarker, therapeutic target, and prognostic indicator in various diseases, particularly tumors. SNHG11 plays a crucial role in the occurrence and development of tumors and inflammatory diseases through various mechanisms, which has significant implications for clinical diagnosis and treatment.PMID:37165588 | DOI:10.2174/1389557523666230509122402
Source: Mini Reviews in Medicinal Chemistry - May 11, 2023 Category: Chemistry Authors: Yinxin Wu Source Type: research